Jan Astermark

Professor, Senior Consultant
Department of Translational Medicine, Lund University, Malmö, Sweden
Malmo, Skane Lan, Sweden

Presentation(s):

• PB0260 - Evaluating Effectiveness and Safety in the Fourth Interim Analysis of the HEM-POWR Study: A Post Hoc Analysis of Patients From Nordic Study Sites

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0203 - NON-INTERVENTIONAL study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 30.5 - Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: updated results from the phase 3 BENEGENE-2 gene therapy trial

  Monday, June 24, 2024
  10:30 – 10:45 ICT

• PB0505 - Long-term joint health outcomes with a recombinant factor VIII Fc from the 48-month prospective, observational A-MORE study: Third interim analysis of up to 24 months

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.5 - Management of breakthrough bleeding episodes in the phase 3 concizumab studies

  Monday, June 24, 2024
  15:45 – 16:00 ICT